Abstract
A 75-year-old female had been treated with Nu-Lotan® (losartanpotassium) for hypertension. One month later, her treatment was changed from Nu-Lotan® to Preminent®(losartanpotassium/hydrochlorothiazide) and she developed pruritic edematous erythema on sun-exposed areas. Three month later eruptions appeared and pigmentations and depigmentations developed on the same areas. The minimal erythema dose (MED) of UVA was decreased to 4.4 J/cm2. On withdrawal of the Preminent®, the MED was normalized. We made a diagnosis of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®.
| Original language | English |
|---|---|
| Pages (from-to) | 482-485 |
| Number of pages | 4 |
| Journal | Nishinihon Journal of Dermatology |
| Volume | 73 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Dec 1 2011 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
A case of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®. / Nakamura, Yoshitaka; Nemoto, Kei; Yokoyama, Emi; Muto, Masahiko.
In: Nishinihon Journal of Dermatology, Vol. 73, No. 5, 01.12.2011, p. 482-485.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A case of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®
AU - Nakamura, Yoshitaka
AU - Nemoto, Kei
AU - Yokoyama, Emi
AU - Muto, Masahiko
PY - 2011/12/1
Y1 - 2011/12/1
N2 - A 75-year-old female had been treated with Nu-Lotan® (losartanpotassium) for hypertension. One month later, her treatment was changed from Nu-Lotan® to Preminent®(losartanpotassium/hydrochlorothiazide) and she developed pruritic edematous erythema on sun-exposed areas. Three month later eruptions appeared and pigmentations and depigmentations developed on the same areas. The minimal erythema dose (MED) of UVA was decreased to 4.4 J/cm2. On withdrawal of the Preminent®, the MED was normalized. We made a diagnosis of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®.
AB - A 75-year-old female had been treated with Nu-Lotan® (losartanpotassium) for hypertension. One month later, her treatment was changed from Nu-Lotan® to Preminent®(losartanpotassium/hydrochlorothiazide) and she developed pruritic edematous erythema on sun-exposed areas. Three month later eruptions appeared and pigmentations and depigmentations developed on the same areas. The minimal erythema dose (MED) of UVA was decreased to 4.4 J/cm2. On withdrawal of the Preminent®, the MED was normalized. We made a diagnosis of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®.
UR - http://www.scopus.com/inward/record.url?scp=84871418970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871418970&partnerID=8YFLogxK
U2 - 10.2336/nishinihonhifu.73.482
DO - 10.2336/nishinihonhifu.73.482
M3 - Article
AN - SCOPUS:84871418970
VL - 73
SP - 482
EP - 485
JO - Nishinihon Journal of Dermatology
JF - Nishinihon Journal of Dermatology
SN - 0386-9784
IS - 5
ER -